Financings in Brief: Norian
This article was originally published in The Gray Sheet
Norian: Closes $19.8 mil. private placement, funds from which are pegged to help support multi-center clinical trials of the firm's Skeletal Repair System, "an injectable bone-mineral substitute designed to simplify, improve or expand the treatments of bone fractures and defects" ("The Gray Sheet" Feb. 20, I&W-3). An ongoing U.S. study is comparing use of the product to conventional treatment in fracture stabilization in over 300 wrist-fracture patients; a separate study planned for the first quarter of 1996 would involve use to augment orthopedic hardware in hip fracture repair. Cupertino, California-based Norian says it hopes to launch SRS "for general use in North America and throughout Europe in 1997 and in Japan and other countries in 1998." Frazier Securities, L.P. was placement agent for the financing...
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.